Xigduo Tablet, Film Coated, Extended Release
Product Images NDC 0310-6225

16 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Xigduo (NDC 0310-6225). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dapagliflozin Chemical Structure (Image 01)

Dapagliflozin Chemical Structure (Image 01)
Chemical structure diagram depicting dapagliflozin and metformin hydrochloride with an associated water molecule. The structure shows detailed atom-level connectivity typical of these active ingredients in XIGDUO XR tablets.*
FDA Label Image

Metformin Hydrochloride Chemical Structure (Image 02)

Metformin Hydrochloride Chemical Structure (Image 02)
Chemical structure of dapagliflozin and metformin hydrochloride, the active ingredients in XIGDUO XR extended-release tablets by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Figure 1 (Image 03)

Figure 1 (Image 03)
A dose-response plot showing dapagliflozin dose (mg) on the x-axis and cumulative excretion in urine of 24-hour urinary glucose (g) on the y-axis. Scatter points differentiate observed values for healthy subjects and subjects with type 2 diabetes mellitus (T2DM). Fitted lines illustrate trends for both groups across varying doses.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line chart depicting adjusted mean change from baseline in HbA1c (%) over 24 weeks of study. Three groups are shown: dapagliflozin 10 mg plus metformin XR, dapagliflozin 10 mg alone, and metformin XR alone. The y-axis shows HbA1c change, and the x-axis shows study weeks. A separate smaller graph on the right shows Week 24 values with confidence intervals (LOCF).*
FDA Label Image

Figure 3: Graph (Figure 3)

Figure 3:  Graph (Figure 3)
This chart displays the adjusted mean change from baseline in HbA1c (%) over a 24-week study period comparing placebo plus metformin versus dapagliflozin 10 mg plus metformin. The graph shows a greater reduction in HbA1c with dapagliflozin plus metformin. A side panel presents the Week 24 least squares mean differences and 95% confidence intervals for each group.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line chart comparing the percentage of patients with event over months from randomization between Dapagliflozin and Placebo groups. The x-axis is labeled "Months from Randomization" and the y-axis "Patients with event (%)". Two lines show data points, with Placebo represented by a dotted line and Dapagliflozin by a solid line. Below the chart, the number of patients at risk at different months is provided for both groups.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph depicting the percentage of patients with an event over time in months from randomization for dapagliflozin compared to placebo. The x-axis represents months from randomization (0 to ~60), and the y-axis shows patients with events as a percentage (0 to 4.5%). Two lines are shown: a solid line for dapagliflozin and a dotted line for placebo, with the placebo line generally trending higher. Below the graph is a table listing the number of patients at risk for each group at various time points.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A line graph comparing the percentage of patients with an event over months from randomization between dapagliflozin and placebo groups. The x-axis represents months from 0 to 32, and the y-axis shows patients with events (%) from 0 to 24. The dapagliflozin group shows a consistently lower event rate than the placebo group. A table below the graph lists patients at risk over time for both groups.*
FDA Label Image

Figure 7 (a) (Figure 7 (a))

Figure 7 (a) (Figure 7 (a))
A line graph comparing the percentage of patients with an event over months from randomization for dapagliflozin versus placebo. The x-axis shows months (0 to 36), and the y-axis shows the percentage of patients with events (0 to 30%). The dapagliflozin line is consistently below the placebo line, indicating fewer events. Patient counts at risk are listed below the x-axis for both groups over time. The hazard ratio with confidence interval and a p-value are noted on the graph.*
FDA Label Image

Figure 7 (b) (Figure 7 (b))

Figure 7 (b) (Figure 7 (b))
A Kaplan-Meier curve chart depicting the percentage of patients with an event over 36 months from randomization, comparing dapagliflozin to placebo. The graph shows two lines, with the placebo line higher than the dapagliflozin line, indicating fewer events in the dapagliflozin group. Below the x-axis, a table displays the number of patients at risk at various time points for both groups. The hazard ratio and p-value comparing dapagliflozin to placebo are also presented.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A forest plot comparing hazard ratios (HR) with 95% confidence intervals (CI) for dapagliflozin versus placebo across different left ventricular ejection fraction (LVEF) percentage categories from two studies, DAPA-HF and DELIVER. The graph shows HR values relative to which treatment is better, with data points and sample sizes (n/N) listed for each LVEF subgroup.*
FDA Label Image

Image-06 (Image 06)

Image-06 (Image 06)
Packaging label for XIGDUO XR extended-release tablets containing 2.5 mg dapagliflozin and 1000 mg metformin hydrochloride. The label indicates the package contains 60 tablets, is prescription only, and instructs that tablets must be swallowed whole without crushing, cutting, or chewing. Manufactured by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Image-07 (Image 07)

Image-07 (Image 07)
Label for XIGDUO XR extended-release tablets containing dapagliflozin and metformin hydrochloride at 5 mg/500 mg strength. The label shows the product name, active ingredients, dosage form, quantity of 30 tablets, and manufacturer AstraZeneca Pharmaceuticals LP. It includes directions to dispense with medication guide and cautions against crushing, cutting, or chewing the tablets.*
FDA Label Image

Image-08 (Image 08)

Image-08 (Image 08)
Label for XIGDUO XR tablets containing dapagliflozin and metformin hydrochloride extended-release, 5 mg/1000 mg strength. The label indicates a 60 tablet count, prescription only, with warnings to not crush, cut, or chew and to swallow whole. Distributed by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Image-09 (Image 09)

Image-09 (Image 09)
Label for XIGDUO XR tablets containing dapagliflozin and metformin hydrochloride extended-release. Dosage strength is 10 mg/500 mg. The label indicates 30 tablets per package, prescription use only, with instructions not to crush, cut, or chew tablets and to swallow whole. Manufactured by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Image-10 (Image 10)

Image-10 (Image 10)
XIGDUO XR (dapagliflozin/metformin HCl extended-release) tablets packaging label showing a 30-count bottle. The label indicates the strength of 10 mg dapagliflozin and 1000 mg metformin HCl per tablet. It includes instructions to dispense with medication guide and a note that tablets must be swallowed whole without crushing, cutting, or chewing. Manufactured by AstraZeneca Pharmaceuticals LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.